These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16107831)

  • 21. Development of prophylactic and therapeutic vaccines against hepatitis C virus.
    Leroux-Roels G
    Expert Rev Vaccines; 2005 Jun; 4(3):351-71. PubMed ID: 16026249
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
    J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hepatitis viruses: live and let die.
    Herzer K; Sprinzl MF; Galle PR
    Liver Int; 2007 Apr; 27(3):293-301. PubMed ID: 17355449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of the genetic restriction of virus-specific T-cell responses in hepatitis C virus infection.
    Neumann-Haefelin C; Thimme R
    Genes Immun; 2007 Apr; 8(3):181-92. PubMed ID: 17230195
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatitis C virus molecular clones: from cDNA to infectious virus particles in cell culture.
    Bartenschlager R
    Curr Opin Microbiol; 2006 Aug; 9(4):416-22. PubMed ID: 16814596
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adaptive immune responses in acute and chronic hepatitis C virus infection.
    Bowen DG; Walker CM
    Nature; 2005 Aug; 436(7053):946-52. PubMed ID: 16107834
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatitis C virus virology and new treatment targets.
    Meier V; Ramadori G
    Expert Rev Anti Infect Ther; 2009 Apr; 7(3):329-50. PubMed ID: 19344246
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Primary cultures of human hepatocytes isolated from hepatitis C virus-infected cirrhotic livers as a model to study hepatitis C infection.
    Raymond VA; Selliah S; Ethier C; Houle R; Jouan L; Maniere T; Lamarre D; Willems B; Bilodeau M
    Liver Int; 2009 Jul; 29(6):942-9. PubMed ID: 19302183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Replication of hepatitis C virus.
    Moradpour D; Penin F; Rice CM
    Nat Rev Microbiol; 2007 Jun; 5(6):453-63. PubMed ID: 17487147
    [TBL] [Abstract][Full Text] [Related]  

  • 31. In vitro replication models for the hepatitis C virus.
    Sheehy P; Mullan B; Moreau I; Kenny-Walsh E; Shanahan F; Scallan M; Fanning LJ
    J Viral Hepat; 2007 Jan; 14(1):2-10. PubMed ID: 17212638
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatitis C virus vaccines--progress and perspectives.
    Fauvelle C; Lepiller Q; Felmlee DJ; Fofana I; Habersetzer F; Stoll-Keller F; Baumert TF; Fafi-Kremer S
    Microb Pathog; 2013 May; 58():66-72. PubMed ID: 23499591
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mechanism of action of interferon and ribavirin in treatment of hepatitis C.
    Feld JJ; Hoofnagle JH
    Nature; 2005 Aug; 436(7053):967-72. PubMed ID: 16107837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cell culture and infection system for hepatitis C virus.
    Kato T; Date T; Murayama A; Morikawa K; Akazawa D; Wakita T
    Nat Protoc; 2006; 1(5):2334-9. PubMed ID: 17406476
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hepatitis C viral kinetic models.
    Herrmann E; Zeuzem S
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S7-8. PubMed ID: 12655337
    [No Abstract]   [Full Text] [Related]  

  • 36. Evaluation systems for anti-HCV drugs.
    Moriishi K; Matsuura Y
    Adv Drug Deliv Rev; 2007 Oct; 59(12):1213-21. PubMed ID: 17720275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HCV-hepatocellular carcinoma: new findings and hope for effective treatment.
    Dash S; Haque S; Joshi V; Prabhu R; Hazari S; Fermin C; Garry R
    Microsc Res Tech; 2005 Nov; 68(3-4):130-48. PubMed ID: 16276514
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cellular models for the screening and development of anti-hepatitis C virus agents.
    Gondeau C; Pichard-Garcia L; Maurel P
    Pharmacol Ther; 2009 Oct; 124(1):1-22. PubMed ID: 19555718
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunology of hepatitis C: clinical significance of T cell response].
    Shin EC
    Korean J Hepatol; 2006 Jun; 12(2):140-53. PubMed ID: 16804339
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vivo clearance of hepatitis C virus nonstructural 3/4A-expressing hepatocytes by DNA vaccine-primed cytotoxic T lymphocytes.
    Ahlen G; Nystrom J; Pult I; Frelin L; Hultgren C; Sallberg M
    J Infect Dis; 2005 Dec; 192(12):2112-6. PubMed ID: 16288375
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.